University of Duisburg-Essen

Economics of Healthcare

Practical Information

Commencing Date:
Essen Germany

Teaching Methodology:

European Fees:
Scholarship Possibilities:

Course Contact

Gudrun Bayer-Kulla

+49 (0) 2302 - 915131


Office Link

University of Duisburg-Essen

University Accreditation: Yes

Centre of Excellence


This course is part of the Master Program - Master of Science in Pharmaceutical Medicine - which can be single booked but also upgraded to a Certificate of Advanced Studies in Pharmaceutical Medicine or a Master Degree (Master of Science) in Pharmaceutical Medicine.


After completion of this module the student will be able · to compare and contrast the different challenges of healthcare expenditure presented in different economies · to differentiate between rare and common diseases, and the barriers and opportunities for developing orphan drugs · to value the role of patient groups in developing new products for rare diseases · to classify the role of the agencies which police the economic viability of existing and new medical technologies · to assess the multidisciplinary nature of pharmacoeconomics and ethical boundaries, and the need for integration of knowledge from a range of health science disciplines in the management of sustainable health service challenges in the 21st century · to analyze the impact on the various stakeholders, including regulators, pharmaceutical companies, healthcare professionals and patients · to assess the fundamental concepts of health care financing and basic health economic principles · to evaluate market access regulations and introduce market access strategies and policies · to evaluate the scientific, socio-ethical, pricing and reimbursement problems related to developing and marketing orphan drugs · to prepare the structure of the global drug development and regulatory framework with emphasis on risk management in the context of benefit/risk assessment and the role of pharmacoeconomics and quality-of-life · to organize the integration of health economics into pharmaceutical R&D process · to analyze health economics and pricing decisions · to assess current trends and new procedures/technologies in health economics in the USA, UK and Europe · to analyze methods utilised in clinical trials for examining cost-effectiveness of new pharmaceutical products · to assess the role of pharmacoepidemiology in the life-cycle management of a medicine · to analyze principles and practical application of health economics and patient-reported outcomes within the pharmaceutical industry · to analyze the legal, economical and ethical considerations for health care spending and allocation decisions · to manage the practical use of health economics and their influence of the health care Systems · to plan quality of life assessments, cost minimisation analysis, cost-effectiveness analysis, cost-utility analysis, cost-benefit analysis, QALYs

IMI Standards

  • A predefined set of teaching objectives, leading to defined learning outcomes
  • Assessment of the students' achievement in accordance with the agreed learning outcomes of the training offered
  • A system for collecting, assessing and addressing feedback from learners, teachers, technical / administrative staff and programme / course / module managers
  • Availability of appropriate and regularly reviewed reference material (e.g. published articles, links, book chapters, scripts, etc)
  • Defined and transparent admission criteria
  • Quality assurance of teaching staff
  • Regular review of the QA/QC process and demonstration that the training is further developed in light of this review
  • The facilities, infrastructure, leadership and competences available for the support of student learning
  • University accreditation OR a system for approving, monitoring and reviewing the training offered